A double blind controlled study of clobazam for the treatment of anxiety in psychiatric outpatients

K. D. Charalampous, C. E. Sermas, W. A. Newsom, G. A. Keepers

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Clobazam, a 1,5 benzodiazepine, was compared to placebo in a double-blind randomized efficacy trial. The thirty patients in the trial had a diagnosis of anxiety neurosis which was at least moderately severe. Fourteen received a placebo and sixteen received the drug in increasing doses for one week. Comparison of the two groups on the basis of pre- and post-treatment Hamilton Anxiety Scores and Clinical Global Improvement Scores indicated definite superiority of clobazam over placebo in the treatment of anxiety. The most common side effects were drowsiness and dizziness.

Original languageEnglish (US)
Pages (from-to)779-785
Number of pages7
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume21
Issue number6
StatePublished - Jan 1 1977

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A double blind controlled study of clobazam for the treatment of anxiety in psychiatric outpatients'. Together they form a unique fingerprint.

  • Cite this